GENINCODE
GEN inCode specializes in cardiovascular disease risk. Cardiovascular disease is the leading cause of death and disability worldwide. GEN inCode products combine genetic and clinical data to risk assess patients and provide healthcare practitioners with advanced clinical information to evaluate and predict the onset of cardiovascular disease. Our products help inform patients of their health risk enabling them to make behavioral or ‘lifestyle’ changes whilst providing doctors with greater ... genetic insight and clinical information to determine the most effective treatment pathway (precision medicine). GEN inCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. Our molecular tests combine clinical algorithms and artificial intelligence to provide an advanced patient risk assessment to predict disease onset.
GENINCODE
Industry:
Biotechnology Health Care Life Science
Founded:
2018-01-01
Address:
Oxford, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.genincode.com
Total Employee:
11+
Status:
Active
Contact:
+44 7800 903435
Email Addresses:
[email protected]
Total Funding:
3.9 M GBP
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Metabolomic Diagnostics
Metabolomic Diagnostics specializes in the development of novel biomarker based diagnostic solutions for complex diseases
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
RNAimmune
RNAimmune is a biopharmaceutical company specializing in the discovery and development of mRNA-based therapeutics and vaccines.
Current Employees Featured
Founder
Investors List
Maven Capital Partners
Maven Capital Partners investment in Private Equity Round - GENinCode
Maven Capital Partners
Maven Capital Partners investment in Private Equity Round - GENinCode
Official Site Inspections
http://www.genincode.com Semrush global rank: 5.08 M Semrush visits lastest month: 1.62 K
- Host name: 26.35.214.35.bc.googleusercontent.com
- IP address: 35.214.35.26
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "GENinCode"
Gen cardiovascular disease testing, prevention, treatment
Sep 20, 2024 GENinCode provides genomic testing for the prevention, diagnosis, and treatment of cardiovascular disease. Harnessing the power of both monogenic and polygenic risk assessment to combat the world’s most …See details»
GENinCode
Jun 4, 2025 GENinCode products provide genetic information to enable patients and healthcare practitioners to assess and predict the onset of cardiovascular disease. Our tests and reports help inform health care practitioners and …See details»
GENinCode - Crunchbase Company Profile & Funding
GENinCode is a genetic testing business specializing in the risk assessment and prediction of cardiovascular disease.See details»
Company number: 11556598 - investors.genincode.com
Mr Foulger joined GENinCode in January 2021, becoming a director in April 2021. He is a seasoned CFO with substantial strategic, entrepreneurial, and commercial experience at …See details»
Genetic Testing For Personalised Health Care and …
Oct 17, 2018 GENinCode test products have been developed to help physicians make improved clinical decisions. By delivering comprehensive risk assessment we are able to stratify patients and identify the most appropriate treatment …See details»
Board of Directors | Genetic Testing For Personalised
Board of Directors Matthew Walls – Chief Executive Officer Mr Walls became Chief Executive Officer of GENinCode on incorporation in September 2018. Between September 2018 and October 2019 he was also Chairman of …See details»
GENINCODE PLC overview - Find and update company …
GENINCODE PLC - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, charges, business activitySee details»
About GENINCODE | DxMultiomics
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide. …See details»
GENinCode (AIM:GENI) Company Profile & Description
Apr 14, 2025 Company profile for GENinCode Plc (AIM:GENI) with a description, list of executives, contact details and other key facts.See details»
Gen cardiovascular disease testing, prevention, treatment
Apr 4, 2023 GENinCode provides genomic testing for the prevention, diagnosis, and treatment of cardiovascular disease. Harnessing the power of both monogenic and polygenic risk …See details»
GEN inCode - 2025 Company Profile - Tracxn
Aug 17, 2021 GEN inCode - Developer of precison medicines by combining genetic and clinical data for cardiac disease monitoring. Public Company. Raised a total funding of $4.48M over 3 …See details»
GENinCode - Team members, CEO, Employees
GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. GENinCode predictive technology provides …See details»
Financial Reports | Genetic Testing For Personalised Health
Jun 30, 2021 UK GENinCode UK Limited Oxford Science Park, John Eccles House Robert Robinson Avenue Oxford, OX4 4GP +44 (0)1865 676 125 SPAIN GENinCode S.L.U. Rambla …See details»
GENinCode - Contacts, Employees, Board Members, Advisors
GENinCode is a genetic testing business specializing in the risk assessment and prediction of cardiovascular disease.See details»
GENinCode - Funding, Financials, Valuation & Investors
GENinCode is a genetic testing business specializing in the risk assessment and prediction of cardiovascular disease.See details»
GENinCode - LGB Co
GENinCode plc, a cardiovascular disease company, focuses on predictive genetics for the prevention of cardiovascular disease. Its technology provides patientsSee details»
GENinCode Plc (“GENinCode” or the “Com
GENinCode Plc (“GENinCode” or the “Company”) Interim Results to 30 June 2021 erim results for the six months ended 30 June 2021. The first half of the 2021 financial year saw GENinCode …See details»
GENinCode shares surge as loss narrows amid increased revenue
Jun 4, 2025 GENinCode PLC shares soared on Wednesday as it reported increased revenue and said it expects a further ‘significant increase’ during 2025. Shares in GENinCode were up …See details»
How Generative AI Is Reshaping Development - Forbes
21 hours ago GenAI is altering how software is made, forcing us to rethink engineering itself.See details»
Genetic Testing For Personalised Health Care and Medicine
May 16, 2025 GENinCode test products have been developed to help physicians make improved clinical decisions. By delivering comprehensive risk assessment we are able to …See details»